(S (NP-SBJ Anti-CD2/JJ receptor/NN antibodies/NNS) (VP activate/VBP (NP (NP the/DT HIV/NN long/JJ terminal/JJ repeat/NN) (PP in/IN (NP T/NN lymphocytes/NNS)))) ./.)
(S (NP-SBJ The/DT CD2/NN T/NN lymphocyte/NN glycoprotein/NN surface/NN molecule/NN) (VP mediates/VBZ (NP (NP-COOD both/CC (NP cell/NN to/TO cell/NN adhesion/NN) and/CC (NP T/NN cell/NN activation/NN)) ,/, (NP (NP two/CD processes/NNS) (SBAR (WHNP-20 that/WDT) (S (NP-SBJ-21 *T*-20/-NONE-) (VP are/VBP (VP involved/VBN (NP *-21/-NONE-) (PP in/IN (NP (NP the/DT spread/NN) (PP of/IN (NP HIV/NN infection/NN))))))))))) ./.)
(S (NP-SBJ-22 (NP Treatment/NN) (PP of/IN (NP (ADJP chronically/RB HIV-infected/JJ) PBMC/NN)) (PP with/IN (NP anti-CD2/JJ mAb/NN))) (VP has/VBZ (VP been/VBN (VP shown/VBN (S (NP-SBJ *-22/-NONE-) (VP to/TO (VP induce/VB (NP (NP the/DT expression/NN) (PP of/IN (NP (NP infectious/JJ virus/NN) (PP from/IN (NP these/DT cultures/NNS))))))))))) ./.)
(S (PP In/IN (NP this/DT study/NN)) (NP-SBJ we/PRP) (VP investigated/VBD (NP (NP the/DT mechanisms/NNS) (SBAR (WHADVP-23 whereby/WRB) (S (NP-SBJ anti-CD2/JJ antibodies/NNS) (VP stimulate/VBP (NP viral/JJ production/NN) (PP *T*-23/-NONE-)))))) ./.)
(S (NP-SBJ We/PRP) (VP demonstrate/VBP (SBAR that/IN (S (NP-SBJ (NP treatment/NN) (PP of/IN (NP (ADJP transiently/RB transfected/VBN) T/NN lymphocytes/NNS)) (PP with/IN (NP anti-CD2/JJ antibodies/NNS))) (VP results/VBZ (PP in/IN (NP (NP activation/NN) (PP of/IN (NP the/DT HIV/NN long/JJ terminal/JJ repeat/NN)))))))) ./.)
(S (ADVP Furthermore/RB) ,/, (NP-SBJ-COOD (NP (NP CAT/NN assays/NNS) (VP using/VBG (NP mutated/VBN HIV/NN (ADJP long/JJ terminal/JJ repeat-CAT/NN) constructs/NNS))) and/CC (NP gel/NN shift/NN assays/NNS)) (VP demonstrate/VBP (SBAR that/IN (S (NP-SBJ this/DT activation/NN) (VP is/VBZ (ADJP-PRD dependent/JJ (PP on/IN (NP the/DT NF-kappa/NN B/NN enhancer/NN))))))) ./.)
(S (NP-SBJ These/DT studies/NNS) (VP suggest/VBP (SBAR that/IN (S (NP-SBJ (NP interaction/NN) (PP of/IN (NP CD2/NN)) (PP with/IN (NP (NP its/PRP$ natural/JJ ligand/NN) ,/, (NP LFA-3/NN) ,/,))) (VP may/MD (VP play/VB (NP a/DT role/NN) (PP in/IN (NP (NP regulation/NN) (PP of/IN (NP HIV/NN expression/NN))))))))) ./.)
